Comerica Bank Grows Stake in Elanco Animal Health Incorporated $ELAN

Comerica Bank increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 46.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,680 shares of the company’s stock after acquiring an additional 15,754 shares during the period. Comerica Bank’s holdings in Elanco Animal Health were worth $522,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Allworth Financial LP lifted its stake in Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after purchasing an additional 2,090 shares during the last quarter. CoreCap Advisors LLC bought a new stake in Elanco Animal Health in the fourth quarter worth about $29,000. NBC Securities Inc. bought a new stake in Elanco Animal Health in the first quarter worth about $40,000. Parallel Advisors LLC lifted its stake in Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock worth $41,000 after purchasing an additional 1,852 shares during the last quarter. Finally, Versant Capital Management Inc lifted its stake in Elanco Animal Health by 65.9% in the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company’s stock worth $46,000 after purchasing an additional 1,740 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN opened at $18.40 on Monday. The company has a market capitalization of $9.14 billion, a price-to-earnings ratio of 21.39, a price-to-earnings-growth ratio of 3.42 and a beta of 1.62. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The firm has a 50 day moving average of $15.95 and a 200 day moving average of $12.94. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $18.87.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same period last year, the firm posted $0.30 EPS. Elanco Animal Health’s revenue for the quarter was up 4.8% compared to the same quarter last year. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, sell-side analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on ELAN shares. Leerink Partnrs raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 17th. Wall Street Zen raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a research note on Saturday, July 5th. Leerink Partners raised shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target for the company in a research note on Thursday, July 17th. Stifel Nicolaus lifted their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, July 2nd. Finally, Zacks Research downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 20th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.33.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.